Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
$ 0.1755 0.001 (0.57%) Market Cap: 16.77 Mil Enterprise Value: 19.54 Mil PE Ratio: 0 PB Ratio: 0.12 GF Score: 34/100

Tonix Pharmaceuticals Holding Corp Business Update Transcript

Dec 07, 2020 / 01:30PM GMT
Release Date Price: $140 (+11.11%)
Operator

Good morning, ladies and gentlemen and welcome to Tonix Pharmaceuticals Conference Call to discuss the result of the Phase 3 RELIEF study. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Peter Vozzo of Weswicke, Investor Relations for Tonix Pharmaceuticals. You may begin.

Peter Vozzo
Tonix Pharmaceuticals Holding Corp - Weswicke, IR

Thank you, [Jamie]. Good morning everyone and thank you for joining us today. We will review results of the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia. Early this morning, the company issued a press relief announcing the result of the study.

On the call with me today are Tonix Pharmaceuticals' President and Chief Executive Officer, Dr. Seth Lederman and Chief Medical Officer, Dr. Greg Sullivan. Today's call is being made available via the Investor Relations section of the company's website at ir

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot